A detailed history of Eaton Vance Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Eaton Vance Management holds 3,333,022 shares of LLY stock, worth $2.49 Billion. This represents 1.6% of its overall portfolio holdings.

Number of Shares
3,333,022
Previous 3,508,620 5.0%
Holding current value
$2.49 Billion
Previous $1.14 Billion 5.26%
% of portfolio
1.6%
Previous 1.6%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $52.1 Million - $59.3 Million
-175,598 Reduced 5.0%
3,333,022 $1.08 Billion
Q2 2022

Aug 15, 2022

SELL
$278.73 - $327.27 $41.5 Million - $48.8 Million
-148,966 Reduced 4.07%
3,508,620 $1.14 Billion
Q1 2022

May 16, 2022

BUY
$234.69 - $291.66 $21.6 Million - $26.8 Million
91,899 Added 2.58%
3,657,586 $1.05 Billion
Q4 2021

Feb 14, 2022

BUY
$224.85 - $279.04 $20 Million - $24.8 Million
88,793 Added 2.55%
3,565,687 $981 Million
Q3 2021

Nov 15, 2021

BUY
$221.6 - $272.71 $31.6 Million - $38.9 Million
142,561 Added 4.28%
3,476,894 $800 Million
Q2 2021

Aug 16, 2021

BUY
$180.55 - $233.54 $10.8 Million - $13.9 Million
59,726 Added 1.82%
3,334,333 $765 Million
Q1 2021

May 17, 2021

BUY
$164.32 - $212.72 $9.56 Million - $12.4 Million
58,196 Added 1.81%
3,274,607 $612 Million
Q4 2020

Feb 12, 2021

BUY
$130.46 - $172.63 $8.92 Million - $11.8 Million
68,354 Added 2.17%
3,216,411 $543 Million
Q3 2020

Nov 13, 2020

BUY
$146.22 - $169.13 $9.8 Million - $11.3 Million
67,044 Added 2.18%
3,148,057 $466 Million
Q2 2020

Nov 20, 2020

BUY
$136.42 - $164.18 $8,867 - $10,671
65 Added 0.0%
3,081,013 $506 Million
Q2 2020

Aug 13, 2020

SELL
$136.42 - $164.18 $28.2 Million - $34 Million
-206,897 Reduced 6.29%
3,080,948 $506 Million
Q1 2020

May 14, 2020

BUY
$119.05 - $147.35 $15.3 Million - $18.9 Million
128,154 Added 4.06%
3,287,845 $456 Million
Q4 2019

Feb 11, 2020

BUY
$106.92 - $132.43 $11.7 Million - $14.4 Million
108,966 Added 3.57%
3,159,691 $415 Million
Q3 2019

Nov 14, 2019

BUY
$106.79 - $116.16 $562,676 - $612,047
5,269 Added 0.17%
3,050,725 $341 Million
Q2 2019

Aug 16, 2019

BUY
$110.79 - $129.32 $8.15 Million - $9.51 Million
73,563 Added 2.48%
3,045,456 $337 Million
Q1 2019

May 14, 2019

SELL
$111.31 - $131.02 $10.1 Million - $11.9 Million
-90,623 Reduced 2.96%
2,971,893 $386 Million
Q4 2018

Feb 07, 2019

SELL
$105.9 - $118.64 $13.3 Million - $14.9 Million
-125,904 Reduced 3.95%
3,062,516 $354 Million
Q3 2018

Nov 13, 2018

BUY
$85.86 - $107.31 $1.53 Million - $1.92 Million
17,848 Added 0.56%
3,188,420 $342 Million
Q2 2018

Aug 10, 2018

SELL
$75.7 - $86.88 $38.8 Million - $44.6 Million
-512,887 Reduced 13.92%
3,170,572 $271 Million
Q1 2018

May 07, 2018

SELL
$74.21 - $87.6 $28.3 Million - $33.4 Million
-381,490 Reduced 9.38%
3,683,459 $285 Million
Q4 2017

Feb 12, 2018

SELL
$81.94 - $87.89 $6.76 Million - $7.25 Million
-82,451 Reduced 1.99%
4,064,949 $343 Million
Q3 2017

Nov 13, 2017

BUY
$77.07 - $85.54 $320 Million - $355 Million
4,147,400
4,147,400 $355 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $711B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Eaton Vance Management Portfolio

Follow Eaton Vance Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.